Pfizer/BioNTech show high immune response in a booster dose against Omicron in clinical trial for children 5-11 years


Pfizer/BioNTech announce positive results for a third dose of their COVID-19 vaccine for children

Grant Paulsen, MD, assistant professor, Division of Infectious Disease, Department of Pediatrics, Cincinnati Children's Hospital Medical Center in Ohio, and primary investigator for the hospital's clinical trial for a third dose (booster) for the Pfizer/BioNTech vaccine for COVID-19, discusses what the data might mean for children aged 5 to 11 years.

Related Videos
Juanita Mora, MD
Importance of maternal influenza vaccination recommendations
Samantha Olson, MPH
© 2024 MJH Life Sciences

All rights reserved.